Vitamin D3 analogues

Clinics in Dermatology

Volumn 15, Issue 5, 1997, Pages 705-713

  Fogh, Karsten ^a   Kragballe, Knud ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLIC GMP; CYCLOSPORIN; DITHRANOL; DNA; ETRETIN; FLUOCINONIDE; HLA ANTIGEN; HYDROCORTISONE BUTYRATE; MESSENGER RNA; PARATHYROID HORMONE; PHOSPHOLIPASE C; PSORALEN; RETINOID X RECEPTOR; TACALCITOL; ULOBETASOL PROPIONATE; VITAMIN D RECEPTOR; COLECALCIFEROL; DRUG DERIVATIVE; VITAMIN D;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCALCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SKIN ATROPHY; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET B RADIATION; ADULT; CHEMISTRY; CHILD; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; PROGNOSIS; SKIN; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; CHILD; CHOLECALCIFEROL; CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PROGNOSIS; PSORIASIS; SKIN; TREATMENT OUTCOME; VITAMIN D;

EID: 0030610511     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00021-7     Document Type: Article

References (110)

1. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986;86:706-16.
2. 3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990;282:164-7.
3. 3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T-lymphocytes following activation. J Clin Endocrinol Metab 1983;57:1308-10.
4. 3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996;1:68-71.
5. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC903). Arch Dermatol 1989;125:1647-52.
6. Kragballe K, Iversen L. Calcipotriol (MC903) a new topical antipsoriatic. Dermatol Clin 1993;11:137-41.
7. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7.
8. 3. Med J Osaka Univ 1985; 35:51.
9. 3. Endocrinology 1983;113: 1950-7.
10. Binderup L, Kragballe K. Origin of the use of calcipotriol in psoriasis treatment. Rev Contemp Pharmacotherap 1992;23:401-9.
11. Evans RM. The steroid and thyroid hormone receptor super-family. Science 1988;240:889-95.
12. Chen ML, Heinrich G, Ohyama Y, et al. Expression of 25-hydroxyvitamin D3-24-hydroxylase mRNA in cultured human keratinocytes. Proc Soc Exp Biol Med 1994; 207:57-61.
13. Darwish H, DeLuca HF. Identification of a 1,25-dihydroxyvitamin D3-response element in the 5′-flanking region of the rat calbindin D-9k gene. Proc Natl Acad Sci USA 1992;89:603-7.
14. 3. Proc Natl Acad Sci USA 1992;89:8097-101.
15. 3. Proc Natl Acad Sci USA 1990;87:369-73.
16. 3. Proc Natl Acad Sci USA 1989;86:4455-9.
17. Ozono K, Liao J, Kerner SA, et al. The vitamin D-responsive element in the human osteocalcin gene. J Biol Chem 1990;265:21881-8.
18. 3 response element of chicken carbonic anhydrase-II. DNA Cell Biol 1994;13: 1181-7.
19. 3 receptors. Cell 1991;65:1255-66.
20. Carlberg C, Bendik I, Wyss A, et al. Two signalling pathways for vitamin D. Nature 1993;361:657-60.
21. Carlberg C, Mathiasen IS, Saurat J-H, et al. The 1,25-dihydroxyvitamin D3 (VD) analogues MC903, EB1089 and KH1060 activate the VD receptor: Homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Biochem Mol Biol 1994;51: 137-42.
22. 3-activated expression of the rat osteocalcin gene. Mol Cell Biol 1993;13:5907-17.
23. Schräder M, Müller KM, Becker-André M, et al. Response element selectivity for heterodimerization of vitamin D receptors with retinoic acid and retinoid X receptors. J Mol Endocrinol 1994;12:327-39.
24. Sone T, Ozono K, Pike JW. A 55-kilodalton accessory factor facilitates vitamin D receptor DNA binding. Mol Endocrinol 1991;5:1578-86.
25. 3 receptor in human skin biopsies. J Clin Endocrinol Metabol 1980;51:1463-5.
26. Dam TN, Møller B, Hindkjær J, et al. The vitamin D analog calcipotriol suppresses the number and antigenpresenting function of Langerhans cells in normal human skin. J Invest Dermatol Symp Proc 1996;1:72-7.
27. 3, alpha-melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol 1988;91: 593-8.
28. Eil C, Marx S. Nuclear uptake of 1,25-dihydroxy cholecalciferol in dispersed fibroblasts cultured form normal human skin. Proc Natl Acad Sci USA 1981;78:2562-66.
29. 3. J Clin Invest 1989;83:1903-15.
30. Barsony J, Marx SJ. Rapid accumulatin of cGMP near activated vitamin D receptors. Proc Natl Acad Sci USA 1991,88:1436-40.
31. 3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol 1992;41:231-40.
32. 3 in rat osteosarcoma cells: structure-function studies using ligand analogs. Endocrinology 1991;129:1876-84.
33. 3: Dependence on cell culture conditions. J Invest Dermatol 1996;106: 510-6.
34. 3 analogs in a cell-density-, calcium- and serum-dependent manner. Pharmacol Toxicol 1997;80:49-56.
35. 3 analogue KH 1060 induce hyperproliferation in normal mouse epidermis. Exp Dermatol 1993,2:113-20.
36. 3. Biochem Pharmacol 1995;49:621-4.
37. 3 in cultured human keratinocytes (submitted).
38. Sølvsten H, Jensen TJ, Sørensen S, et al. Application of calcipotriol to normal human skin increases the level of the vitamin D receptor (VDR) and the binding of the VDR-retinoid X receptor heterodimer to a vitamin D response element (submitted).
39. 3: A novel immunoregulatory hormone. Science 1984;14:38-40.
40. 3 treated monocytes. Arthritis Rheum 1992;35:110-9.
41. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889-95.
42. Binderup L, Carlberg C, Kissmeyer A, et al. The need for new vitamin D analogues: mechanisms of action and clinical application. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D. New York: Walter de Gruyter, 1994:55-63.
43. 3 analogues in transfected cultures of human keratinocytes. Skin Pharmacol 1997;10:12-20.
44. 3 on the growth of human keratinocytes. J Dermatol 1990;17:97-103.
45. 3 with high activity for inducing epidermal differentiation but decreased hypercalcemia activity. J Dermatol 1990; 17:135-42.
46. 3 receptors in normal and psoriatic skin. J Invest Dermatol 1991;97:230-6.
47. Solvsten H, Fogh K, Svendsen M, et al. Normal levels of the vitamin D receptor and its message in psoriatic skin. J Invest Dermatol Symp Proc 1996;1:28-32.
48. Jensen TJ, Sølvsten H, Kragballe K. Correlation between vitamin D receptor and retinoid X receptor levels and binding to DNA in psoriatic skin. Br J Dermatol (submitted).
49. 3 level. J Dermatol Sci 1990;1:277-82.
50. Staberg B, Oxholm A, Klemp P, et al. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol (Stockh) 1987;67:65-8.
51. Smith EL, Pincus SH, Donovan L, et al. A novel approach for the evaluation and treatment of psoriasis. J Am Acad Dermatol 1988;10:360-4.
52. Guilhou JJ, Colette C, Monpoint S, et al. Vitamin D metabolism in psoriasis before and after phototherapy. Acta Derm Venereol (Stockh) 1990;70:351-4.
53. Risum G. Psoriasis excerbated by hypoparathyrodism with hypocalcemia. Br J Dermatol 1973;89:309-12.
54. Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcenvia-induced pustular psoriasis of von Zumbusch. Ann Intern Med 1984;100:677-80.
55. Mortensen L, Kragballe K, Wegman E, et al. Treatment of psoriasis vulgaris with topical calcipotriol has no shortterm effect on calcium and bone metabolism. Acta Derm Venereol (Stockh) 1993;73:300-4.
56. 3 of cultured psoriatic epidermal keratinocytes from involved and uninvolved skin. J Clin Endocrinol Metab 1989;68:851-4.
57. 3. Proc Natl Acad Sci USA 1985;82:5409-12.
58. 3 in psoriasis. Arch Dermatol 1990;126:1107-8.
59. Langner A, Verjans H, Stapar V, et al. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. Br J Dermatol 1993;128:566-71.
60. 3 treatment in psoriasis vulgaris. Br J Dermatol 1986;115:421-9.
61. 3 in psoriasis. Br J Dermatol 1989;120:661-4.
62. Henderson CA, Papworth-Smith J, Cunliffe WJ, et al. A double-blind placebo-controlled trial of topical 1,25-dihydroxycalciferol in psoriasis. Br J Dermatol 1989;121:493-6.
63. 3 ointment. In: Norman AW, Bouillon R, Thomasset N, editors. Vitamin D: Gene regulation structure - function analysis and clinical application. Berlin: Walter de Gruyter, 1991:430-1.
64. 3) ointment in psoriasis: a safety, tolerance and efficacy multicentre study. Dermatology 1994;188:135-9.
65. Bourke JF, Featherstone S, Iqbal SJ, et al. A double-blind comparison of topical calcitriol (3 μ-g/g) and calcipotriol (50 μg/g) in the treatment of chronic plaque psoriasis vulgaris (abstract). Br J Dermatol 1995;133 (suppl 45):17.
66. Langner A, Ashton P, van de Kerkhof PCM, et al. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 1996;135:385-9.
67. 3. A review of our experience. Arch Dermatol 1989;125:231-4.
68. 3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070-8.
69. 3 analogue (MC903) in a double-blind study. Br J Dermatol 1988;199:223-30.
70. Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with MC 903, a new vitamin D analogue. Acta Derm Venereol (Stockh) 1989;69:147-50.
71. Harrington CI, Goldin D, Lovell CR, et: al. Comparative effects of two different calcipotriol (MC903) cream formulations versus placebo in psoriasis vulgaris. A randomized, double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol 1996;6:152-8.
72. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7.
73. Klaber MR, Hutchinson PE, Pedvis-Leftick, et al. Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83.
74. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC903) ointment in psoriasis vulgaris. J Am Acad Dermatol 1992;27:983-8.
75. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right-left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6.
76. Ortonne JP. Psoriasis: new therapeutic modality by calcipotriol and betamethasone dipropionate. Nouv Dermatol 1994;13:746-51.
77. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755-9.
78. Lebwohl M, Siskin SB, Epinette W. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-9.
79. Berth-Jones J, Chu AC, Dodd WAH, et al. A multicentre parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-71.
80. Van der Vleuten CJM, de Jong EMGJ, Ruto EHFC, et al. In-patient treatment with calcipotriol versus dithranol in refractory psoriasis. Eur J Dermatol 1995;5:676-9.
81. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-6.
82. Nielsen PG. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis. Acta Derma Venereol (Stockh) 1993;73:394.
83. Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 1990;181:211-4.
84. Molin L. Calcipotriol combined with phototherapy (UVB and PUVA) in the treatment of psoriasis (abstract). J Eur Acad Dermatol 1995:S5 (suppl):184.
85. Kerscher M, Volkenandt M, Plewig G. Combination phototherapy of psoriasis with calcipotriol and narrowband UVB (letter). Lancet 1993;343:923.
86. Kokelj F, Lavaroni G, Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venereol (Stockh) 1995;75:386-7.
87. Koo J. Phototherapy in combination with vitamin D therapy. J Am Acad Dermatol (in press).
88. McKenna KE, Stern RS. Photosensitivity associated with combined UV-B and calcipotriene therapy. Arch Dermatol 1995;131:1305-7.
89. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994;130:79-82.
90. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double-blind placebo study in severe psoriasis. Eur J Dermatol 1993;3:351-4.
91. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68-74.
92. 3. Cell Immunol 1989;121:290-7.
93. Van de Kerkhof PCM, Hutchinson PE. Topical use of calcipotriol improves outcome in acitretin treated patients with severe psoriasis vulgaris (abstract). Br J Dermatol 1996;135 (suppl):30.
94. Kragballe K, Fogh K. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Acta Dermatol Venereol (Stockh) 1991;71:475-8.
95. Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque-type psoriasis. Dermatology 1994;189:260-4.
96. Cunliffe WJ, Claudy A, Fairiss G, et al. A multicentre comparative study of calcipotriol and betamethasone 17-valerate in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-43.
97. Fullerton A, Avnstorp C, Agner T, et al. Patch test study with calcipotriol ointment in different patient groups, including psoratic patients with and without adverse dermatitis. Acta Derm Venereol (Stockh) 1996;76:194-202.
98. Dwyer C, Chapman RS. Calcipotriol and hypercalcemia. Lancet 1991;338:764-5.
99. Gumowski-Sunek D, Rizzoli R, Saurat JH. Effects of topical calcipotriol on calcium metabolism in psoriatic patients: Comparison with oral calcitriol. Dermatologica 1991;183:275-9.
100. Berth-Jones J, Bourke JF, Iqbal SJ, et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993;129:411-4.
101. Bourke JF, Berth-Jones J, Mumford R, et al. High dose topical consistently reduces serum, parathyroid hormone levels. Clin Endocrinol 1994;41:295-7.
102. Hardman KH, Heath DA. Hypercalcemia associated with calcipotriol (Dovonex) treatment (letter). Br Med J 1993;306:896.
103. Russell S, Young MJ. Hypercalcemia during treatment of psoriasis with calcipotriol. Br J Dermatol 1994;130:795-6.
104. Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol (Dovonex®) in treating children with psoriasis vulgaris. Br J Dermatol 1996;135:390-3.
105. 3 analogue, 1, 24-dihydroxy cholecalciferol. Br J Dermatol 1986;115:431-3.
106. 3 for the treatment of psoriasis. A review of the literature. Eur J Dermatol 1993;3:255-61.
107. Baadsgaard O, Traulsen J, Roed-Petersen J, et al. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatol Treat 1995;6:145-50.
108. Scarpa C. Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996;6:142-6.
109. TV-02 Ointment Research Group. A placebo controlled double-blind, right-left comparison study on the efficacy of TV-02 ointment for the treatment of psoriasis. Nishinihon J Dermatol 1991;53:1252-6.
110. Nishimura M, Makino Y, Matugi H. Tacalcitol ointment for psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186:166-8.